We have located links that may give you full text access.
Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Atherosclerosis. Supplements 2015 May
BACKGROUND: Lipoprotein apheresis (LA) therapy is effective in eliminating atherogenic lipoproteins and reducing the rate of cardiovascular events (CVE) in patients suffering from severe hypercholesterolemia or increased lipoprotein(a) (Lp(a)) levels despite maximal tolerated lipid lowering therapy.
METHODS: We examined the rate of CVE in 116 patients (63% males) with an isolated increase of LDL-cholesterol (LDL-C) (Group 1), an isolated increase of Lp(a) (Group 2), a combined increase of LDL-C and Lp(a) (Group 3) and patients who were referred for LA, but never started (Group 4).
RESULTS: Patients with increased Lp(a) (Groups 2 and 3) showed a higher prevalence of advanced atherosclerotic changes, defined as involvement of 3 or 4 vascular territories, including the abdominal aorta and leg arteries, and an involvement of more coronary vessels compared to patients in group 1. Prior to initiation of LA, on average patients suffered 4.4 (range: 0-14) CVE during a period of 7.2 (range: 0-41) years. Group 1 patients suffered fewer CVE per patient-year compared to the other groups (Group 1: 0.75, Group 2: 1.7, Groups 3 and 4: 1.4). 55-63% of patients applying for LA experienced a CVE within the last year (on average 1.3 CVE per patient in the last year). Among patients referred to LA there is a high rate of intolerance to nicotinic acid (42% of patients in Group 3) and statins (58% of patients in Group 1).
CONCLUSION: Patients referred to LA represent a high risk population for CVE in all vascular territories. Increased Lp(a) levels cause a higher percentage of patients with advanced atherosclerosis.
METHODS: We examined the rate of CVE in 116 patients (63% males) with an isolated increase of LDL-cholesterol (LDL-C) (Group 1), an isolated increase of Lp(a) (Group 2), a combined increase of LDL-C and Lp(a) (Group 3) and patients who were referred for LA, but never started (Group 4).
RESULTS: Patients with increased Lp(a) (Groups 2 and 3) showed a higher prevalence of advanced atherosclerotic changes, defined as involvement of 3 or 4 vascular territories, including the abdominal aorta and leg arteries, and an involvement of more coronary vessels compared to patients in group 1. Prior to initiation of LA, on average patients suffered 4.4 (range: 0-14) CVE during a period of 7.2 (range: 0-41) years. Group 1 patients suffered fewer CVE per patient-year compared to the other groups (Group 1: 0.75, Group 2: 1.7, Groups 3 and 4: 1.4). 55-63% of patients applying for LA experienced a CVE within the last year (on average 1.3 CVE per patient in the last year). Among patients referred to LA there is a high rate of intolerance to nicotinic acid (42% of patients in Group 3) and statins (58% of patients in Group 1).
CONCLUSION: Patients referred to LA represent a high risk population for CVE in all vascular territories. Increased Lp(a) levels cause a higher percentage of patients with advanced atherosclerosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app